WO2001089551A1 - Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes - Google Patents

Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes Download PDF

Info

Publication number
WO2001089551A1
WO2001089551A1 PCT/US2001/005825 US0105825W WO0189551A1 WO 2001089551 A1 WO2001089551 A1 WO 2001089551A1 US 0105825 W US0105825 W US 0105825W WO 0189551 A1 WO0189551 A1 WO 0189551A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
zonulin
diabetes
peptide antagonist
rats
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/005825
Other languages
English (en)
French (fr)
Inventor
Alessio Fasano
Tammara L. Watts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland Baltimore
University of Maryland College Park
Original Assignee
University of Maryland Baltimore
University of Maryland College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2001249067A priority Critical patent/AU2001249067A1/en
Priority to JP2001585794A priority patent/JP2003534287A/ja
Priority to AT01922244T priority patent/ATE438405T1/de
Priority to EP01922244A priority patent/EP1282432B1/en
Priority to US10/275,877 priority patent/US7026294B2/en
Priority to DE60139466T priority patent/DE60139466D1/de
Priority to CA002409771A priority patent/CA2409771C/en
Application filed by University of Maryland Baltimore, University of Maryland College Park filed Critical University of Maryland Baltimore
Publication of WO2001089551A1 publication Critical patent/WO2001089551A1/en
Anticipated expiration legal-status Critical
Priority to US11/346,395 priority patent/US7531512B2/en
Priority to US12/165,088 priority patent/US20080269136A1/en
Priority to US12/536,158 priority patent/US8183211B2/en
Priority to US13/461,343 priority patent/US20130157943A1/en
Priority to US14/070,212 priority patent/US20140128321A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/843—Digestive system
    • Y10S530/844—Stomach; intestine

Definitions

  • the peptide antagonist was able to effectively block the permeability changes required for the development of diabetes; and (2) in those rats treated with the peptide antagonist, the levels of intraluminal zonulin are 3 -fold higher than the treated rats that did not develop diabetes. In this population of treated rats that developed diabetes, the amount of peptide antagonist may not have been enough to block a sufficient number of ZOT/zonulin receptors necessary to prevent diabetes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
PCT/US2001/005825 2000-05-19 2001-03-21 Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes Ceased WO2001089551A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AU2001249067A AU2001249067A1 (en) 2000-05-19 2001-03-21 Method of use of peptide antagonists of zonulin to prevent or delay the onset ofdiabetes
JP2001585794A JP2003534287A (ja) 2000-05-19 2001-03-21 糖尿病発症を予防または遅延させるためのゾヌリンのペプチドアンタゴニストの使用方法
AT01922244T ATE438405T1 (de) 2000-05-19 2001-03-21 Verwendung von peptidantagonisten des zonulin zur behandlung von diabetes
EP01922244A EP1282432B1 (en) 2000-05-19 2001-03-21 Use of peptide antagonists of zonulin for prevention or delay of the onset of diabetes
US10/275,877 US7026294B2 (en) 2000-05-19 2001-03-21 Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
DE60139466T DE60139466D1 (de) 2000-05-19 2001-03-21 Behandlung von diabetes
CA002409771A CA2409771C (en) 2000-05-19 2001-03-21 Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
US11/346,395 US7531512B2 (en) 2000-05-19 2006-02-03 Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
US12/165,088 US20080269136A1 (en) 2000-05-19 2008-06-30 Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
US12/536,158 US8183211B2 (en) 2000-05-19 2009-08-05 Pharmaceutical compositions for inhibiting intestinal permeability
US13/461,343 US20130157943A1 (en) 2000-05-19 2012-05-01 Method and use of peptide antagonists of zonolin to prevent or delay the onset of diabetes
US14/070,212 US20140128321A1 (en) 2000-05-19 2013-11-01 Method and use of peptide antagonists of zonulin to prevent or delay the onset of diabetes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20530500P 2000-05-19 2000-05-19
US60/205,305 2000-05-19

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10275877 A-371-Of-International 2001-03-21
US11/346,395 Continuation US7531512B2 (en) 2000-05-19 2006-02-03 Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes

Publications (1)

Publication Number Publication Date
WO2001089551A1 true WO2001089551A1 (en) 2001-11-29

Family

ID=22761653

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/005825 Ceased WO2001089551A1 (en) 2000-05-19 2001-03-21 Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes

Country Status (8)

Country Link
US (6) US7026294B2 (enExample)
EP (1) EP1282432B1 (enExample)
JP (3) JP2003534287A (enExample)
AT (1) ATE438405T1 (enExample)
AU (1) AU2001249067A1 (enExample)
CA (1) CA2409771C (enExample)
DE (1) DE60139466D1 (enExample)
WO (1) WO2001089551A1 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006135811A3 (en) * 2005-06-09 2007-03-08 Univ Maryland Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells
US7294689B2 (en) * 2003-07-15 2007-11-13 University Of Maryland, Baltimore Agonist polypeptide of receptor for Zot and Zonulin
WO2007095092A3 (en) * 2006-02-09 2008-09-12 Alba Therapeutics Corp Formulations for a tight junction effector
WO2009065949A3 (en) * 2007-11-21 2009-07-30 Solvay Peptide production and purification process
US8034776B2 (en) 2006-10-26 2011-10-11 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease
US20130295594A1 (en) * 2005-05-13 2013-11-07 Alba Therapeutics Corporation Methods and compositions for the diagnosis of crohn's disease
AU2012203787B2 (en) * 2006-02-09 2014-07-10 Alba Therapeutics Corporation Formulations for a Tight Junction Effector
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
WO2019199642A1 (en) * 2018-04-09 2019-10-17 Innovate Biopharmaceuticals Inc. Compositions and methods for treating or preventing hyperglycemia, insulin resistance, and associated organ damage

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458925B1 (en) * 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
WO2001089551A1 (en) * 2000-05-19 2001-11-29 University Of Maryland, Baltimore Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
WO2008043107A2 (en) * 2006-10-06 2008-04-10 Alba Therapeutics Corporation Use of tight junction antagonists to treat inflammatory bowel disease
EP2091551B1 (en) * 2006-11-03 2020-01-15 Alba Therapeutics Corporation Method of treating asthma
AT504214B1 (de) * 2007-01-03 2008-04-15 Bernhard Hans Peter Dipl Ing D Verfahren zur dynamischen, datenabhängigen bestimmung und anwendung von berechtigungen in hierarchischen und relationalen umgebungen
US8728491B2 (en) * 2007-05-07 2014-05-20 Alba Therapeutics Corporation Transcutaneous delivery of therapeutic agents
US20110201543A1 (en) * 2007-06-29 2011-08-18 Blake Paterson Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress
US8198233B2 (en) 2007-07-26 2012-06-12 Alba Therapeutics Corporation Synthetic peptides that enhance tight junction permeability
WO2009137436A2 (en) * 2008-05-05 2009-11-12 Alba Therapeutics Corporation Peptide conjugates
US8957032B2 (en) 2008-05-06 2015-02-17 Alba Therapeutics Corporation Inhibition of gliadin peptides
US20190358288A1 (en) 2017-02-10 2019-11-28 Innovate Biopharmaceuticals, Inc. Compositions and methods for treating or preventing environmental enteropathy
KR20180107341A (ko) * 2017-03-16 2018-10-02 차의과학대학교 산학협력단 칼륨 경쟁적 위산분비억제제를 유효성분을 함유하는 장 누수 증후군 치료 및 예방용 조성물
WO2019165346A1 (en) 2018-02-23 2019-08-29 Innovate Biopharmaceuticals, Inc. Compounds and methods for treating tight junction permeability

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037196A1 (en) * 1995-05-24 1996-11-28 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of use of the same
US5945510A (en) * 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions
WO2000007609A1 (en) * 1998-08-03 2000-02-17 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936065A (en) * 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
ES2168456T3 (es) * 1995-01-16 2002-06-16 North Sydney Area Health Serv Peptidos que afectan a los linfocitos t.
ATE408617T1 (de) * 1996-06-11 2008-10-15 Northern Sydney And Central Co T zell antigen rezeptor peptide
WO2001089551A1 (en) * 2000-05-19 2001-11-29 University Of Maryland, Baltimore Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
US7025294B2 (en) * 2003-05-20 2006-04-11 Carter Day International, Inc. Hammermill with stub shaft rotor apparatus and method
CN101420850A (zh) * 2006-02-09 2009-04-29 阿尔巴医疗公司 紧密连接效应子的制剂
WO2008043107A2 (en) * 2006-10-06 2008-04-10 Alba Therapeutics Corporation Use of tight junction antagonists to treat inflammatory bowel disease
WO2008052185A2 (en) * 2006-10-26 2008-05-02 Alba Therapeutics Corp Materials and methods for the treatment of celiac disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037196A1 (en) * 1995-05-24 1996-11-28 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of use of the same
US5665389A (en) * 1995-05-24 1997-09-09 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of treating diabetes
US5945510A (en) * 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions
WO2000007609A1 (en) * 1998-08-03 2000-02-17 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Chromatography of Peptides and Proteins: Separation Analysis and Conformation", 1991, C.R.C. PRESS
"High Performance .Liquid.. Chromatography of Peptides and. Proteins: Separation Analysis and Conformation", 1991, C. R. C . PRESS

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7777001B2 (en) 2003-07-15 2010-08-17 University Of Maryland, Baltimore Agonist polypeptide of receptor for ZOT and zonulin
US7294689B2 (en) * 2003-07-15 2007-11-13 University Of Maryland, Baltimore Agonist polypeptide of receptor for Zot and Zonulin
EP1648917A4 (en) * 2003-07-15 2008-11-12 Univ Maryland AGONISTPOLYPEPTIDE OF THE RECEPTOR FOR ZOT AND ZONULIN
AU2004259705B2 (en) * 2003-07-15 2009-04-23 University Of Maryland, Baltimore Agonist polypeptide of receptor for zot and zonulin
US20130295594A1 (en) * 2005-05-13 2013-11-07 Alba Therapeutics Corporation Methods and compositions for the diagnosis of crohn's disease
WO2006135811A3 (en) * 2005-06-09 2007-03-08 Univ Maryland Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells
US8168594B2 (en) 2006-02-09 2012-05-01 Alba Therapeutics Corporation Method for treating celiac disease
US9265811B2 (en) 2006-02-09 2016-02-23 Alba Therapeutics Corporation Formulations for a tight junction effector
AU2007215304B2 (en) * 2006-02-09 2012-06-14 Alba Therapeutics Corporation Formulations for a tight junction effector
WO2007095092A3 (en) * 2006-02-09 2008-09-12 Alba Therapeutics Corp Formulations for a tight junction effector
KR101393652B1 (ko) * 2006-02-09 2014-05-14 알바 쎄러퓨틱스 코포레이션 폐쇄연접 효과기용 제제
AU2012203787B2 (en) * 2006-02-09 2014-07-10 Alba Therapeutics Corporation Formulations for a Tight Junction Effector
EP2777695A1 (en) * 2006-02-09 2014-09-17 Alba Therapeutics Corporation Formulations for a tight junction effector
TWI478721B (zh) * 2006-02-09 2015-04-01 Alba Therapeutics Corp 細胞緊密連接效應劑之配方
US9241969B2 (en) 2006-02-09 2016-01-26 Alba Therapeutics Corp. Method for treating celiac disease
US8034776B2 (en) 2006-10-26 2011-10-11 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease
US9279807B2 (en) 2006-10-26 2016-03-08 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease
WO2009065949A3 (en) * 2007-11-21 2009-07-30 Solvay Peptide production and purification process
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
WO2019199642A1 (en) * 2018-04-09 2019-10-17 Innovate Biopharmaceuticals Inc. Compositions and methods for treating or preventing hyperglycemia, insulin resistance, and associated organ damage

Also Published As

Publication number Publication date
ATE438405T1 (de) 2009-08-15
US20060128626A1 (en) 2006-06-15
US8183211B2 (en) 2012-05-22
EP1282432A4 (en) 2005-06-08
US20140128321A1 (en) 2014-05-08
EP1282432A1 (en) 2003-02-12
US20050065074A1 (en) 2005-03-24
CA2409771C (en) 2008-12-02
DE60139466D1 (de) 2009-09-17
CA2409771A1 (en) 2001-11-29
EP1282432B1 (en) 2009-08-05
US7531512B2 (en) 2009-05-12
US20080269136A1 (en) 2008-10-30
JP2011213742A (ja) 2011-10-27
JP2008074869A (ja) 2008-04-03
US20100087380A1 (en) 2010-04-08
JP2003534287A (ja) 2003-11-18
US20130157943A1 (en) 2013-06-20
AU2001249067A1 (en) 2001-12-03
US7026294B2 (en) 2006-04-11

Similar Documents

Publication Publication Date Title
US8183211B2 (en) Pharmaceutical compositions for inhibiting intestinal permeability
US6458925B1 (en) Peptide antagonists of zonulin and methods for use of the same
US20060287233A1 (en) Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells
MXPA01001321A (en) Peptide antagonists of zonulin and methods for use of the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 585794

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001922244

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2409771

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2001922244

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10275877

Country of ref document: US